General Information of Drug (ID: DMRD8HK)

Drug Name
TAK-683 Drug Info
Synonyms
(5S)-6-[6-[(1E,3R,5Z)-3-Hydroxyundeca-1,5-dienyl]pyridin-2-yl]hexane-1,5-diol; U 75302; U-75302; 119477-85-9; (5S)-6-[6-[(1E,3R,5Z)-3-hydroxyundeca-1,5-dienyl]pyridin-2-yl]hexane-1,5-diol; 6-(6-(3-Hydroxy-1,5-undecadien-1-yl)-2-pyridinyl)-1,5-hexanediol; U75302; AC1O6A9C; SCHEMBL1894359; GTPL3325; ZINC4489632; SR-01000946976; SR-01000946976-1; 1,5-Hexanediol, 6-(6-(3-hydroxy-1,5-undecadienyl)-2-pyridinyl)-,
Indication
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Discontinued in Phase 1 [1]
Allergy 4A80-4A85 Terminated [2]
Cross-matching ID
PubChem CID
49787129
TTD Drug ID
DMRD8HK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Investigative Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
kisspeptin-10 DMDL21W Discovery agent N.A. Investigative [5]
4-fluorobenzoyl-Phe-Gly-Leu-Arg-Trp-NH2 DMWD42N Discovery agent N.A. Investigative [6]
Drug Name Drug ID Indication ICD 11 Highest Status REF
LTB4 DME26RS Human immunodeficiency virus infection 1C62 Phase 2 [7]
Amelubant DMUMCB9 Pulmonary disease 1B10-1F85 Phase 2 [8]
Biomed 101 DMQ9KZW Kidney cancer 2C90.0 Phase 1 [9]
LY293111 DM03FHA Pancreatic cancer 2C10 Discontinued in Phase 2 [10]
SB-201993 DMIF4VJ Psoriasis vulgaris EA90 Discontinued in Phase 2 [11]
CI-949 DMN4QSW Asthma CA23 Discontinued in Phase 2 [12]
CP-195543 DM1OSUR Rheumatoid arthritis FA20 Discontinued in Phase 2 [13]
LTB 019 DM6G0PN Asthma CA23 Discontinued in Phase 2 [14]
LY-223982 DMWB7DO Asthma CA23 Discontinued in Phase 2 [15]
CP-105696 DM1C4IN Inflammatory bowel disease DD72 Discontinued in Phase 1 [16]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
G-protein coupled receptor 54 (KISS1R) TT3KBZY KISSR_HUMAN Agonist [3]
Leukotriene B4 receptor 1 (LTB4R) TTN53ZF LT4R1_HUMAN Antagonist [4]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028256)
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3325).
3 Clinical pipeline report, company report or official report of Takeda (2009).
4 A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med. 2000 Aug 7;192(3):421-32.
5 The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J Biol Chem. 2001 Sep 14;276(37):34631-6.
6 Development of novel G-protein-coupled receptor 54 agonists with resistance to degradation by matrix metalloproteinase. J Med Chem. 2008 Dec 11;51(23):7645-9.
7 LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat Med. 2015 Mar;21(3):239-47.
8 Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects. Paediatr Drugs. 2005;7(6):353-63.
9 Biomed 101, a leukotriene B4 inhibitor, may decrease IL-2 toxicity. 2003 ASCO Annual Meeting. 2003.
10 The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer. PPAR Res. 2008;2008:827096.
11 (E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist w... J Med Chem. 1996 Sep 13;39(19):3837-41.
12 Inhibition of histamine, leukotriene C4/D4, and thromboxane B2 release from human leukocytes and human chopped lung mast cells by the allergic mediator release inhibitor, CI-949. J Allergy Clin Immunol. 1990 Dec;86(6 Pt 1):902-8.
13 The synthesis of CP-195543, an LTB4 antagonist for the treatment of inflammatory diseases. Curr Opin Drug Discov Devel. 1999 Nov;2(6):550-6.
14 Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2008;21(2):409-17.
15 Specific inhibition of leukotriene B4-induced neutrophil activation by LY223982. J Pharmacol Exp Ther. 1992 Dec;263(3):1009-14.
16 3-Substituted-4-hydroxy-7-chromanylacetic acid derivatives as antagonists of the leukotriene B4 (LTB4) receptor, Bioorg. Med. Chem. Lett. 7(17):2307-2312 (1997).